bioRxiv · 10.1101/2025.10.16.682926
Integrated phenotypic and proteomic screening identifies top-tier Alzheimer's disease therapeutic targets
Abstract
IntroductionAlzheimers disease (AD) is a complex neurodegenerative disorder. Hundreds of therapeutic targets have been nominated through genetic and multi-omic studies, but effective prioritization remains a major bottleneck. MethodsWe applied an integrative screening framework to assess 29 candidate targets from risk-enriched biological domains. Using disease-relevant murine BV2 microglial cell lines with stable Psen2 knockdown, we performed siRNA-mediated perturbations followed by cellular phenotypic assays and quantitative proteomics. ResultsTwenty-five candidate targets significantly altered at least one phenotype, with stronger effects in Psen2 knockdown cells. Integrated proteomic analyses identified several perturbations that reversed AD-associated molecular patterns. Five targets--Ap2a2, Pdhb, Pdha1, Dlat, and Psmc3-- impacted both phenotypes and related proteomic responses. DiscussionWe established a scalable platform for target functional validation that bridges unbiased systems-level assessments of AD risk with experimental evidence. The ESSJ TREAT-AD center will prioritize further resource development for these validated targets.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Cary, G. A., Li, Q., Wiley, J. C., Paisie, C. A., Du, Y., Zoeller, E. L., Duong, D., Fu, H., Seyfried, N. T., Levey, A. I., Betarbet, R., Carter, G. W.. 2025-10-16. Integrated phenotypic and proteomic screening identifies top-tier Alzheimer's disease therapeutic targets. https://doi.org/10.1101/2025.10.16.682926
Cite the original work for its findings. Save a collection to share your selection of sources.